6.
Zhang J, Olatosi B, Yang X, Weissman S, Li Z, Hu J
. Studying patterns and predictors of HIV viral suppression using A Big Data approach: a research protocol. BMC Infect Dis. 2022; 22(1):122.
PMC: 8817473.
DOI: 10.1186/s12879-022-07047-5.
View
7.
Baum M, Rafie C, Lai S, Sales S, Page J, Campa A
. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses. 2010; 26(5):511-8.
PMC: 2875959.
DOI: 10.1089/aid.2009.0211.
View
8.
Nicholas S, Poulet E, Wolters L, Wapling J, Rakesh A, Amoros I
. Point-of-care viral load monitoring: outcomes from a decentralized HIV programme in Malawi. J Int AIDS Soc. 2019; 22(8):e25387.
PMC: 6706700.
DOI: 10.1002/jia2.25387.
View
9.
Mujugira A, Celum C, Tappero J, Ronald A, Mugo N, Baeten J
. Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships. AIDS Res Hum Retroviruses. 2015; 32(2):148-54.
PMC: 4761836.
DOI: 10.1089/AID.2015.0296.
View
10.
Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G
. Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015. BMC Infect Dis. 2017; 17(1):326.
PMC: 5415758.
DOI: 10.1186/s12879-017-2428-3.
View
11.
Liu T, Chambers L, Hansen B, Bazerman L, Cachay E, Christopoulos K
. Risk of HIV Viral Rebound in the Era of Universal Treatment in a Multicenter Sample of Persons With HIV in Primary Care. Open Forum Infect Dis. 2023; 10(6):ofad257.
PMC: 10284343.
DOI: 10.1093/ofid/ofad257.
View
12.
. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017; 4(8):e349-e356.
PMC: 5555438.
DOI: 10.1016/S2352-3018(17)30066-8.
View
13.
Opoku S, Sakyi S, Ayisi-Boateng N, Enimil A, Senu E, Ansah R
. Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana. AIDS Res Ther. 2022; 19(1):21.
PMC: 9131580.
DOI: 10.1186/s12981-022-00447-2.
View
14.
Wainberg M, Zaharatos G, Brenner B
. Development of antiretroviral drug resistance. N Engl J Med. 2011; 365(7):637-46.
DOI: 10.1056/NEJMra1004180.
View
15.
Nachega J, Hislop M, Nguyen H, Dowdy D, Chaisson R, Regensberg L
. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009; 51(1):65-71.
PMC: 2674125.
DOI: 10.1097/QAI.0b013e318199072e.
View
16.
Henrich T, Wood B, Kuritzkes D
. Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL. PLoS One. 2012; 7(11):e50065.
PMC: 3499490.
DOI: 10.1371/journal.pone.0050065.
View
17.
Farhadian M, Mohammadi Y, Mirzaei M, Shirmohammadi-Khorram N
. Factors related to baseline CD4 cell counts in HIV/AIDS patients: comparison of poisson, generalized poisson and negative binomial regression models. BMC Res Notes. 2021; 14(1):114.
PMC: 7992967.
DOI: 10.1186/s13104-021-05523-w.
View
18.
Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine M, Costagliola D
. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000; 133(6):401-10.
DOI: 10.7326/0003-4819-133-6-200009190-00007.
View
19.
Nguyen M, McNaughton Reyes H, Pence B, Muessig K, Hutton H, Latkin C
. The longitudinal association between depression, anxiety symptoms and HIV outcomes, and the modifying effect of alcohol dependence among ART clients with hazardous alcohol use in Vietnam. J Int AIDS Soc. 2021; 24 Suppl 2:e25746.
PMC: 8222856.
DOI: 10.1002/jia2.25746.
View
20.
Min S, Gillani F, Aung S, Garland J, Beckwith C
. Evaluating HIV Viral Rebound Among Persons on Suppressive Antiretroviral Treatment in the Era of "Undetectable Equals Untransmittable (U = U)". Open Forum Infect Dis. 2020; 7(12):ofaa529.
PMC: 7731526.
DOI: 10.1093/ofid/ofaa529.
View